



Rachel Rosenthal

Kontakt

Rachel Rosenthal

Publikationen (11)

Viehl C, Oertli D, Sauter G, Terracciano L, Langer I, Banz V, Ramser M, Rosenthal R, Dell-Kuster S, Gueller U, Weixler B, Zuber M. Presence of bone marrow micro-metastases in stage I-III colon cancer patients is associated with worse disease-free and overall survival. *Cancer Med* 2017; 6:918-927.

Franzeck F, Rosenthal R, Muller M, Nocito A, Wittich F, Maurus C, Dindo D, Clavien P, Hahnloser D. Prospective randomized controlled trial of simulator-based versus traditional in-surgery laparoscopic camera navigation training. *Surg Endosc* 2011; 26:235-41.

Adamina M, Spagnoli G, Marti W, Oertli D, Heberer M, Jacob A, Huegli R, Bolli M, Viehl C, Frey D, Weber W, Rosenthal R, Zajac P. Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma. *Mol Ther* 2010; 18:651-9.

Rosenthal R, Heberer M, Oertli D, von Holzen U, Frey D, Weber W, Bolli M, Iezzi G, Zajac P, Feder-Mengus C, Adamina M, Bracci L, Groeper C, Spagnoli G. Differential responsiveness to IL-2, IL-7, and IL-15 common receptor gamma chain cytokines by antigen-specific peripheral blood naive or memory cytotoxic CD8+ T cells from healthy donors and melanoma patients. *J Immunother* 2009; 32:252-61.

Bracci L, Belardelli F, Proietti E, Iezzi G, Zajac P, Groeper C, Rosenthal R, Adamina M, Provenzano M, Schumacher R, Spagnoli G. Efficient stimulation of T cell responses by human IFN-alpha-induced dendritic cells does not require Toll-like receptor triggering. *J Immunother* 2008; 31:466-74.

Rosenthal R, Viehl C, Gueller U, Weber W, Adamina M, Spagnoli G, Heberer M, Zuber M. Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal. *J Am Coll Surg* 2008; 207:95-105.

Adamina M, Heberer M, Zuber M, Oertli D, Frey D, Gueller U, Zajac P, Schumacher R, Rosenthal R, Weber W, Spagnoli G. Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial. *Contemp Clin Trials* 2007; 29:165-81.

Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R, Zerkowski H, Heberer M, Spagnoli G. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. *Int J Cancer* 2007; 120:337-43.

Adamina M, Oertli D, Spagnoli G, Amacker M, Zurbriggen R, Feder C, Groeper C, Rosenthal R, Weber W, Zajac P, Schumacher R, Heberer M. Advanced liposomal vectors as cancer vaccines in melanoma immunotherapy. *J Liposome Res* 2006; 16:195-204.

Adamina M, Daetwiler S, Rosenthal R, Zajac P. Clinical applications of recombinant virus-based cancer immunotherapy. *Expert Opin Biol Ther* 2005; 5:1211-24.

Schumacher R, Amacker M, Neuhaus D, Rosenthal R, Groeper C, Heberer M, Spagnoli G, Zurbriggen R, Adamina M. Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro. *Vaccine* 2005; 23:5572-82.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch